FDA Brief

Warning letters Drugs

FDA warning letter to

Wholesale Peptide

High riskIssued Jun 17Posted Jun 23Center for Drug Evaluation and Research (CDER)

FDA warns Wholesale Peptide that its website sells Prostamax and Gonadorelin as unapproved new drugs.

What happened

FDA reviewed the company's website, wholesalepeptide.com, in May 2026 rather than conducting an inspection. The agency found pages for Prostamax and Gonadorelin that describe them as treating prostate inflammation and enlarged prostate and as affecting testosterone and testes function, which makes them drugs. FDA says no approved application exists for either product, so they are unapproved new drugs and cannot be sold across state lines.

What FDA found

  1. Prostamax and Gonadorelin are drugs because the website says they treat disease and affect how the body works.

    Section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1); 21 CFR 201.128
  2. Neither product is generally recognized as safe and effective for its labeled use, so both are 'new drugs'.

    Section 201(p) of the FD&C Act, 21 U.S.C. 321(p)
  3. Neither product has an FDA-approved application, yet the company offers them for sale.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  4. Offering these unapproved drugs for sale and shipping them across state lines is prohibited.

    Sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a)
  5. Labels saying 'Research Use Only' and 'not for human consumption' do not override the website claims that the products are meant for human use as drugs.

    21 CFR 201.128

What FDA wants

FDA tells the company to investigate the root causes, fix the violations, and send a written response with the steps taken and documentation within 15 business days, citing reference number 729447.

Who should pay attention

  • online peptide and supplement sellers who make health claims
  • clinics and researchers buying peptides from websites
  • brands relying on 'research use only' disclaimers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk